National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Nivolumab (Opdivo®) for Melanoma

Opdivo® is indicated as for monotherapy treatment for patients diagnosed with unresectable metastatic melanoma.

Rapid Review

Commenced Completed Outcome
28/05/2015 16/07/2015 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
30/10/2015  18/03/2016 Reimbursement not recommended at the submitted price.


The HSE has approved reimbursement following confidential price negotiations October 2017.